Amneal Pharmaceuticals Inc (AMRX)
6.815
+0.06
(+0.96%)
USD |
NASDAQ |
May 17, 16:00
6.815
0.00 (0.00%)
After-Hours: 20:00
Amneal Pharmaceuticals Enterprise Value: 4.738B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 4.738B |
| May 16, 2024 | 4.716B |
| May 15, 2024 | 4.753B |
| May 14, 2024 | 4.747B |
| May 13, 2024 | 4.704B |
| May 10, 2024 | 4.688B |
| May 09, 2024 | 4.630B |
| May 08, 2024 | 4.667B |
| May 07, 2024 | 4.642B |
| May 06, 2024 | 4.685B |
| May 03, 2024 | 4.719B |
| May 02, 2024 | 4.550B |
| May 01, 2024 | 4.522B |
| April 30, 2024 | 4.500B |
| April 29, 2024 | 4.466B |
| April 26, 2024 | 4.444B |
| April 25, 2024 | 4.454B |
| April 24, 2024 | 4.500B |
| April 23, 2024 | 4.299B |
| April 22, 2024 | 4.290B |
| April 19, 2024 | 4.306B |
| April 18, 2024 | 4.287B |
| April 17, 2024 | 4.318B |
| April 16, 2024 | 4.315B |
| April 15, 2024 | 4.343B |
| Date | Value |
|---|---|
| April 12, 2024 | 4.336B |
| April 11, 2024 | 4.389B |
| April 10, 2024 | 4.392B |
| April 09, 2024 | 4.401B |
| April 08, 2024 | 4.485B |
| April 05, 2024 | 4.522B |
| April 04, 2024 | 4.472B |
| April 03, 2024 | 4.491B |
| April 02, 2024 | 4.426B |
| April 01, 2024 | 4.500B |
| March 31, 2024 | 4.503B |
| March 28, 2024 | 4.419B |
| March 27, 2024 | 4.438B |
| March 26, 2024 | 4.354B |
| March 25, 2024 | 4.373B |
| March 22, 2024 | 4.422B |
| March 21, 2024 | 4.490B |
| March 20, 2024 | 4.425B |
| March 19, 2024 | 4.505B |
| March 18, 2024 | 4.373B |
| March 15, 2024 | 4.246B |
| March 14, 2024 | 4.212B |
| March 13, 2024 | 4.215B |
| March 12, 2024 | 4.188B |
| March 11, 2024 | 4.209B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.659B
Minimum
Apr 12 2023
4.753B
Maximum
May 15 2024
3.284B
Average
3.216B
Median
Enterprise Value Benchmarks
| Fate Therapeutics Inc | 60.40M |
| Ocular Therapeutix Inc | 539.23M |
| Editas Medicine Inc | 166.01M |
| AnaptysBio Inc | 330.21M |
| AEON Biopharma Inc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -91.64M |
| Revenue (Quarterly) | 659.19M |
| Total Expenses (Quarterly) | 575.96M |
| EPS Diluted (Quarterly) | -0.30 |
| Gross Profit Margin (Quarterly) | 36.11% |
| Profit Margin (Quarterly) | -13.90% |
| Earnings Yield | -10.85% |
| Operating Earnings Yield | 18.31% |
| Normalized Earnings Yield | -7.252 |